These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
427 related articles for article (PubMed ID: 16418182)
1. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen. Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182 [TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526 [TBL] [Abstract][Full Text] [Related]
3. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Park JH; Lee JL Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Lee JL; Ahn JH; Park SH; Lim HY; Kwon JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H Invest New Drugs; 2012 Oct; 30(5):1984-90. PubMed ID: 22012004 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma. Alva A; Daignault S; Smith DC; Hussain M Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901 [TBL] [Abstract][Full Text] [Related]
6. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G; Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232 [TBL] [Abstract][Full Text] [Related]
8. [Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy]. Ito H; Aoki Y; Oyama N; Miwa Y; Akino H; Yokoyama O Gan To Kagaku Ryoho; 2011 Mar; 38(3):481-4. PubMed ID: 21403460 [TBL] [Abstract][Full Text] [Related]
9. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707 [TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer. Murad AM Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402 [TBL] [Abstract][Full Text] [Related]
11. Current and future perspectives in advanced bladder cancer: is there a new standard? von der Maase H Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002 [TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065 [TBL] [Abstract][Full Text] [Related]
14. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319 [TBL] [Abstract][Full Text] [Related]
15. Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis. Miyata Y; Nomata K; Ohba K; Matsuo T; Sagara Y; Kanetake H; Sakai H Cancer Chemother Pharmacol; 2012 Sep; 70(3):451-9. PubMed ID: 22864875 [TBL] [Abstract][Full Text] [Related]
16. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group. Boukovinas I; Androulakis N; Vamvakas L; Papakotoulas P; Ziras N; Polyzos A; Kalykaki A; Kotsakis A; Xenidis N; Gioulmbasanis I; Mavroudis D; Georgoulias V Ann Oncol; 2006 Nov; 17(11):1687-92. PubMed ID: 16968872 [TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer. Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958 [TBL] [Abstract][Full Text] [Related]